2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2228 Cumulative treatment-altering toxicities in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies

Doris K. Hansen, MD, Lin Wang, MD, PhD2, Gaurav Deshpande, PhD3, Sandy Wong, MD4, Rahul Banerjee, MD5
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 Bristol Myers Squibb, Princeton, New Jersey, United States
3 Bristol Myers Squibb, Princeton, New Jersey, United States
4 Bristol Myers Squibb, Princeton, New Jersey, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States

Introduction: T cell-redirecting bispecific antibodies (BsAbs) targeting BCMA or GPRC5D have transformed the treatment of relapsed/refractory multiple myeloma (RRMM), with expanding use as monotherapy and combination therapy across earlier lines. BsAbs carry distinct toxicities: BCMA-targeting agents can cause immunosuppression, hypogammaglobulinemia, and infections; GPRC5D-targeting agents can cause dysgeusia, epithelial toxicity, and weight loss; continuously dosing BsAbs may cause cumulative toxicities. We characterized the longitudinal safety burden and outcomes of BsAb therapy in real-world patients (pts) with an emphasis on the incidence and timing of adverse events (AEs) that led to treatment modification or discontinuation.

Methods: This retrospective study used the Cancer Outcomes Tracking and Analysis (COTA) Vantage database (de-identified EHR data; Jan 1, 2018–Nov 30, 2025) to identify pts with RRMM and ≥ 3 prior lines of therapy (pLOT) who received BsAb monotherapy. Index date was the earliest BsAb administration; pts who received BsAbs as CAR T bridging were excluded. Outcomes assessed were baseline characteristics, event-free survival (EFS; time from index to progression, subsequent LOT, or death), overall survival (OS), and the type/incidence of treatment-altering AEs causing unplanned treatment modification/discontinuation.

Results: 219 pts were identified, 136 received BCMA BsAbs (teclistamab, 118; elranatamab, 18) and 83 received GPRC5D BsAbs (talquetamab). Median age was 69 y overall (BCMA, 71 y; GPRC5D, 66 y); 51.6% were male, 62.1% were White, 73.5% had ECOG PS 0–1, and 34.2% had high-risk cytogenetics. Overall, pts were heavily pretreated; median pLOT was 6 (range 3–19) and proportions of triple-class exposed (98.2%) and triple-class refractoriness (28.8%) were similar across groups. Median follow-up was 9.0 mo (BCMA, 8.4 mo; GPRC5D, 9.7 mo). Median EFS was 7.4 mo overall (95% CI, 5.2–10.9): 8.8 mo (BCMA) and 6.8 mo (GPRC5D). Median OS was 31.4 mo overall (95% CI, 21.3–not reached [NR]): 31.4 mo (BCMA) and NR (GPRC5D). Treatment-altering AEs occurred in 58.0% of pts (n=127; mean 7 AEs, 5 unique AE types/patient) and led to discontinuation due to toxicity in 22.4% (n=49); rates were similar between BCMA (57.4%) and GPRC5D (59.0%), but discontinuation due to toxicity was more common with BCMA (26.5% vs 15.7%). Infection was the leading treatment-altering AE overall and markedly more frequent with BCMA than GPRC5D BsAbs (32.4% vs 16.9%), reflecting greater immunosuppression. Common treatment-altering AEs were shared across both classes, occurring at broadly comparable rates between BCMA and GPRC5D BsAbs, respectively: CRS (11% vs 16.9%), neutropenia (15.4% vs 10.8%), pain (14.7% vs 15.7%), fatigue (14.0% vs 13.3%), and fever (12.5% vs 13.3%). Dysgeusia (10.8%) was unique to GPRC5D BsAb therapy. Toxicity accrued early and persisted: a treatment-altering AE occurred in 50% of pts by 3.7 mo (BCMA) and 2 mo (GPRC5D), increasing to 59.0% and 63.9% by 12 mo and continuing to increase thereafter, affecting 1 in 10 BCMA pts at month 30 and 1 in 5 GPRC5D pts at month 15. Infection followed distinct trajectories by target: GPRC5D-related infections clustered early and had largely resolved by 12 mo, whereas BCMA-related infections continued at a steady rate throughout follow-up, with new cases emerging beyond 12 mo and out to month 30, reflecting persistent immunosuppression. Dysgeusia persisted for 15 mo with GPRC5D BsAbs.

Conclusions: In heavily pretreated RRMM, BsAb monotherapy provided modest disease control but caused frequent, cumulative, class-specific toxicity, persisting beyond step-up dosing: persistent infection risk with BCMA BsAbs, dysgeusia/epithelial toxicity with GPRC5D BsAbs. Limitations of our analysis include evolving BsAb de-escalation patterns and lack of information around immunoglobulin G replacement therapy. Regardless, these findings reinforce the role of single-infusion CAR T therapy or time-limited BsAb therapies to avoid cumulative toxicities from T cell redirection.

Doris K. Hansen, MD: BMS - Research Funding; BMS, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech - Research Funding; Johnson & Johnson - Research Funding; Janssen - Research Funding; Adaptive - Research Funding; Kite - Research Funding; Karyopharm - Research Funding; Kite - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); BMS, Janssen, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Legend biotech - Consultancy (Includes expert testimony)